Research and Development
Announcement by Sumitomo Pharma America, Inc. (SMPA) Regarding the U.S. Orphan Drug Designation for an Allogeneic iPS cell-derived Retinal Sheet (3-dimensional retina) as a Treatment for Retinitis Pigmentosa
Research and Development
2026.03.24
SMPA announced on 23 March 2026 that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Desig…
Announcement on the Approval for Manufacturing and Marketing Authorization of the Allogeneic iPS Cell-Derived Dopaminergic Neural Progenitor Cell Product “AMCHEPRY®” in Japan
Research and Development
2026.03.06
Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Toru Kimura; “Sumitomo Pharma”) and R…
Announcement on the Submission of the Application of Manufacturing and Marketing Authorization for Allogeneic iPS Cell-Derived dopaminergic neural progenitor cells in Japan
Research and Development
2025.12.24
Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; “Sumitomo Pharma”) and RACTHERACo., Ltd. (Head Office: C…